OTC:EVFM | Free Cash Flow | Evofem Biosciences, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2013-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31$2.3M$2,000.00$2.3M
2025-12-31$31,000.00$3,000.00$28,000.001.00%
2025-03-31$560,000.00
2024-12-31-$2.41M$0.00-$2.41M
2024-03-31$123,000.00$14,000.00$109,000.00
2023-12-31-$170,000.00$0.00-$170,000.00
2023-03-31-$4.94M$3,000.00-$4.94M
2022-12-31-$6.53M$35,000.00-$6.57M
2022-03-31-$20.92M$66,000.00-$20.99M
2021-12-31-$21.27M$53,000.00-$21.32M
2021-03-31-$34.46M$956,000.00-$35.41M
2020-12-31-$39.08M$1.42M-$40.5M
2020-03-31-$14.88M$95,000.00-$14.97M
2019-12-31-$13.45M$141,000.00-$13.59M
2019-03-31-$7.68M
2018-12-31-$10.25M$7,000.00-$10.25M
2018-03-31-$18.14M
2017-12-31-$4.95M$0.00-$4.95M
2017-03-31-$6.07M
2016-12-31-$2.89M
2016-03-31-$7.61M
2015-12-31-$13.58M$0.00-$13.58M
2015-03-31-$4.8M$226,128.00-$5.03M
2014-12-31-$3.15M$11,166.00-$3.16M
2014-03-31-$2.78M$2,618.00-$2.79M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$1.99M$5,000.00-$2M-510.74%
2024-12-31-$3.89M$14,000.00-$3.9M
2023-12-31-$8.97M$4,000.00-$8.97M-16.94%
2022-12-31-$70.41M$341,000.00-$70.75M
2021-12-31-$146.67M$2.94M-$149.61M
2020-12-31-$104.83M$2.25M-$107.08M
2019-12-31-$55.1M$164,000.00-$55.26M
2018-12-31-$56.5M$7,000.00-$56.51M
2017-12-31-$19.24M$6,000.00-$19.25M
2016-12-31-$16.25M
2015-12-31-$37.91M$226,128.00-$38.14M
2014-12-31-$9.57M$18,078.00-$9.59M
2013-12-31-$12.9M$21,157.00-$12.93M